Lazard Capital Downgrades Abiomed (ABMD) to Hold
More News related to ABMD
- Abiomed to Present at the 21st Annual Piper Jaffray Healthcare Conference
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
- Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Downgrades
- American Equity (AEL) Declares $0.08 Dividend; 1% Yield
- Stage Stores (SSI) Declares $0.05 Quarterly Dividend; 1.6% Yield
- Univest Corp. (UVSP) Declares $0.20 Quarterly Dividend; 5.1% Yield
- Abington Bancorp (ABBC) Declares $0.05 Quarterly Dividend; 0.7% Yield
- Westar Energy (WR) Declares $0.30 Quarterly Dividend; 5.8% Yield
Lazard Capital downgrades Abiomed (Nasdaq: ABMD) from Buy to Hold.
To see more analyst ratings on ABMD Click Here.
Abiomed Inc. is a provider of medical devices in circulatory support that offers a continuum of care in heart recovery to heart failure patients.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
